WO2023072043A8 - Médicament combiné pour traitement de tumeurs - Google Patents
Médicament combiné pour traitement de tumeurs Download PDFInfo
- Publication number
- WO2023072043A8 WO2023072043A8 PCT/CN2022/127280 CN2022127280W WO2023072043A8 WO 2023072043 A8 WO2023072043 A8 WO 2023072043A8 CN 2022127280 W CN2022127280 W CN 2022127280W WO 2023072043 A8 WO2023072043 A8 WO 2023072043A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treating tumors
- combined drug
- drug
- combined
- anlotinib
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 7
- 239000003814 drug Substances 0.000 title abstract 7
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- KSMZEXLVHXZPEF-UHFFFAOYSA-N 1-[[4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)C=CN=C2C=C1OCC1(N)CC1 KSMZEXLVHXZPEF-UHFFFAOYSA-N 0.000 abstract 2
- 229940124618 Anlotinib Drugs 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 abstract 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 abstract 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 abstract 1
- 229960002949 fluorouracil Drugs 0.000 abstract 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 abstract 1
- 235000008191 folinic acid Nutrition 0.000 abstract 1
- 239000011672 folinic acid Substances 0.000 abstract 1
- 229960005277 gemcitabine Drugs 0.000 abstract 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 1
- 229960004768 irinotecan Drugs 0.000 abstract 1
- 229960001691 leucovorin Drugs 0.000 abstract 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 abstract 1
- 229960001756 oxaliplatin Drugs 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention concerne un médicament combiné pour le traitement de tumeurs, comprenant une protéine hybride anticorps anti-PD-L1-TGFβRII, de la gemcitabine et de l'abraxane, et éventuellement, comprenant en outre de l'anlotinib ou un sel pharmaceutiquement acceptable de celui-ci. L'invention concerne également un médicament combiné pour le traitement de tumeurs, comprenant une hybride anticorps anti-PD-L1-TGFβRII, de l'acide folinique, du fluorouracile, de l'irinotécan et de l'oxaliplatine, et éventuellement, comprenant en outre de l'anlotinib ou un sel pharmaceutiquement acceptable de celui-ci. L'invention concerne en outre une trousse pour le traitement de tumeurs, comprenant le médicament combiné. De plus, l'invention concerne l'utilisation du médicament combiné dans la préparation d'un médicament pour le traitement des tumeurs et une méthode de traitement de tumeurs par l'utilisation du médicament combiné.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111247635.8 | 2021-10-26 | ||
| CN202111247635 | 2021-10-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2023072043A1 WO2023072043A1 (fr) | 2023-05-04 |
| WO2023072043A8 true WO2023072043A8 (fr) | 2024-02-15 |
Family
ID=86160385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2022/127280 WO2023072043A1 (fr) | 2021-10-26 | 2022-10-25 | Médicament combiné pour traitement de tumeurs |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2023072043A1 (fr) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2903408T3 (es) * | 2016-02-25 | 2022-04-01 | Cell Medica Switzerland Ag | Miembros de unión para PD-L1 |
| EP3878461A4 (fr) * | 2018-11-09 | 2022-08-17 | Jiangsu Hengrui Medicine Co., Ltd. | COMPOSITION PHARMACEUTIQUE À BASE D'UNE PROTÉINE DE FUSION DU RÉCEPTEUR TGF-ß ET SON UTILISATION |
| JP2022524761A (ja) * | 2019-03-07 | 2022-05-10 | アドヴェンチェン ファーマスーティカルズ，エルエルシー | 癌治療のための標準的な化学療法または免疫療法と組み合わせたカテケンチニブ（アンロチニブ）の順次使用 |
| WO2021037184A1 (fr) * | 2019-08-30 | 2021-03-04 | 正大天晴药业集团南京顺欣制药有限公司 | PROTÉINE DE FUSION CIBLANT PD-L1 ET TGF-β ET SON UTILISATION. |
| BR112022011775A2 (pt) * | 2019-12-20 | 2022-08-30 | Ares Trading Sa | Composição de proteína de fusão igg:tgfssrii |
| WO2021164701A1 (fr) * | 2020-02-18 | 2021-08-26 | Nanjing GenScript Biotech Co., Ltd. | Protéines de fusion et leurs utilisations |
| CN113318226A (zh) * | 2020-02-28 | 2021-08-31 | 正大天晴药业集团股份有限公司 | 抗pd-l1抗体联合放射性射线治疗肺癌的方法 |
| CN114984204A (zh) * | 2021-03-02 | 2022-09-02 | 正大天晴药业集团股份有限公司 | 治疗肿瘤的联用药物 |
| CN112940134B (zh) * | 2021-05-11 | 2021-09-03 | 正大天晴药业集团南京顺欣制药有限公司 | 针对PD-1和TGF-β的双功能蛋白 |
-
2022
- 2022-10-25 WO PCT/CN2022/127280 patent/WO2023072043A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023072043A1 (fr) | 2023-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200020B1 (ar) | ميوتينات إنترليوكين-21 وطرق العلاج | |
| IL275379B2 (en) | Benzylamino-converted pyridopyrimidinones and novel antecedents as sos1 inhibitors | |
| CA3139348A1 (fr) | Composes heterocycliques, leurs procedes de preparation et leurs utilisations | |
| EP3936504A4 (fr) | Dérivés de pyrazolo[1,5-a]pyridine, leur procédé de préparation et leur utilisation | |
| WO2021086833A8 (fr) | Inhibiteurs à petites molécules de mutant de kras g12c | |
| WO2018081417A3 (fr) | Procédé de préparation de pyrazolo[1,5-a]pyrimidines et de sels de celles-ci | |
| IS8132A (is) | Pýrósóló-kínasólín afleiður, aðferð við framleiðslu þeirra og notkun sem kínasa hindrar | |
| CY1116554T1 (el) | Αλατα κλοπιδογρελης και μεθοδος παρασκευης | |
| BRPI0507071A (pt) | derivados de pirazol[1,5-a]pirimidin-7-il-amina para emprego no tratamento de doenças dependentes de proteìna cinase | |
| SI1509521T1 (sl) | 1H-imidazo(4,5-C)kinolinski derivati za zdravljenje od protein kinaze odvisnih bolezni | |
| MY143206A (en) | 1h-thieno 2,3-c pyrazole derivatives useful as kinase i inhibitors | |
| EP3730623A4 (fr) | D'acide hyaluronique à petite molécule ou sel correspondant et son procédé de préparation | |
| CA2555262C (fr) | Derives de 1h-thieno[2,3-c]pyrazole utilises en tant qu'inhibiteurs de kinases | |
| WO2006016067A3 (fr) | Derives de pyrido-pyrimidine, leur preparation, leur application dans le traitement du cancer | |
| SG10201809189UA (en) | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use | |
| IL310079A (en) | TIM-3 antagonists for the treatment and diagnosis of cancer | |
| SG11201810793XA (en) | Pharmaceutical combinations | |
| EP4159203A4 (fr) | Composition orale à libération prolongée pour un médicament insoluble, et son procédé de préparation | |
| EP3842434A4 (fr) | Polymorphe cristallin de chlorhydrate de 8-bromo-2-(1-méthylpipéridin-4-ylamino)-4-(4-phénoxyphénylamino)pyrido[4,3-d]pyrimidin-5(6h)-one et procédé de préparation associé | |
| EP4079734A4 (fr) | Dérivé de triazolopyridazine, son procédé de préparation, composition pharmaceutique associée et utilisation correspondante | |
| WO2021181233A3 (fr) | Protéines de fusion et leurs utilisations | |
| MX2020011453A (es) | Combinaciones para tratar el cancer. | |
| EA202090383A1 (ru) | Усовершенствованный способ получения производных аминопиримидина | |
| WO2023072043A8 (fr) | Médicament combiné pour traitement de tumeurs | |
| Brose et al. | A Phase 1b/2 Trial of Lenvatinib Plus Pembrolizumab in Non-Small Cell Lung Cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22885920 Country of ref document: EP Kind code of ref document: A1 |